🇺🇸 FDA
Pipeline program

Rapid Acting insulin with pre-treatment of rHuPH20

HALO-117-406

Approved small_molecule completed

Quick answer

Rapid Acting insulin with pre-treatment of rHuPH20 for Type 1 Diabetes Mellitus is a Approved program (small_molecule) at HALOZYME THERAPEUTICS, INC. with 1 ClinicalTrials.gov record(s).

Program details

Company
HALOZYME THERAPEUTICS, INC.
Indication
Type 1 Diabetes Mellitus
Phase
Approved
Modality
small_molecule
Status
completed

Clinical trials